WuXi Biologics (Cayman) Inc
HKEX:2269
Income Statement
Earnings Waterfall
WuXi Biologics (Cayman) Inc
Revenue
|
17B
CNY
|
Cost of Revenue
|
-10.2B
CNY
|
Gross Profit
|
6.8B
CNY
|
Operating Expenses
|
-2.4B
CNY
|
Operating Income
|
4.4B
CNY
|
Other Expenses
|
-1B
CNY
|
Net Income
|
3.4B
CNY
|
Income Statement
WuXi Biologics (Cayman) Inc
Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||
Revenue |
1 619
N/A
|
2 019
+25%
|
2 534
+26%
|
3 087
+22%
|
3 984
+29%
|
4 321
+8%
|
5 612
+30%
|
8 075
+44%
|
10 290
+27%
|
13 090
+27%
|
15 269
+17%
|
16 554
+8%
|
17 034
+3%
|
|
Gross Profit | ||||||||||||||
Cost of Revenue |
(958)
|
(1 208)
|
(1 517)
|
(1 813)
|
(2 325)
|
(2 546)
|
(3 079)
|
(4 033)
|
(5 461)
|
(7 144)
|
(8 545)
|
(9 683)
|
(10 206)
|
|
Gross Profit |
661
N/A
|
811
+23%
|
1 018
+25%
|
1 274
+25%
|
1 659
+30%
|
1 775
+7%
|
2 533
+43%
|
4 042
+60%
|
4 829
+19%
|
5 945
+23%
|
6 724
+13%
|
6 871
+2%
|
6 828
-1%
|
|
Operating Income | ||||||||||||||
Operating Expenses |
(222)
|
(282)
|
(321)
|
(368)
|
(597)
|
(655)
|
(888)
|
(1 128)
|
(1 520)
|
(1 719)
|
(2 166)
|
(2 493)
|
(2 415)
|
|
Selling, General & Administrative |
(175)
|
(214)
|
(270)
|
(344)
|
(451)
|
(523)
|
(727)
|
(1 015)
|
(1 157)
|
(1 274)
|
(1 691)
|
(1 950)
|
(2 109)
|
|
Research & Development |
(74)
|
(94)
|
(169)
|
(222)
|
(260)
|
(275)
|
(304)
|
(295)
|
(502)
|
(657)
|
(683)
|
(753)
|
(786)
|
|
Other Operating Expenses |
28
|
27
|
118
|
198
|
114
|
144
|
143
|
181
|
139
|
212
|
208
|
210
|
480
|
|
Operating Income |
439
N/A
|
529
+21%
|
697
+32%
|
906
+30%
|
1 062
+17%
|
1 120
+5%
|
1 645
+47%
|
2 914
+77%
|
3 309
+14%
|
4 226
+28%
|
4 558
+8%
|
4 378
-4%
|
4 413
+1%
|
|
Pre-Tax Income | ||||||||||||||
Interest Income Expense |
(119)
|
(37)
|
97
|
100
|
65
|
250
|
321
|
405
|
684
|
639
|
800
|
586
|
(186)
|
|
Non-Reccuring Items |
(16)
|
(20)
|
(56)
|
(41)
|
0
|
(51)
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(54)
|
|
Pre-Tax Income |
304
N/A
|
473
+56%
|
738
+56%
|
965
+31%
|
1 127
+17%
|
1 320
+17%
|
1 966
+49%
|
3 319
+69%
|
3 993
+20%
|
4 865
+22%
|
5 358
+10%
|
4 957
-7%
|
4 174
-16%
|
|
Net Income | ||||||||||||||
Tax Provision |
(51)
|
(63)
|
(107)
|
(134)
|
(116)
|
(28)
|
(273)
|
(474)
|
(485)
|
(618)
|
(808)
|
(690)
|
(603)
|
|
Income from Continuing Operations |
253
|
410
|
630
|
830
|
1 010
|
1 292
|
1 693
|
2 845
|
3 509
|
4 247
|
4 550
|
4 267
|
3 571
|
|
Income to Minority Interest |
0
|
0
|
0
|
1
|
3
|
8
|
(4)
|
(50)
|
(120)
|
(166)
|
(130)
|
(115)
|
(171)
|
|
Net Income (Common) |
253
N/A
|
410
+62%
|
631
+54%
|
831
+32%
|
1 014
+22%
|
1 300
+28%
|
1 689
+30%
|
2 795
+65%
|
3 388
+21%
|
4 081
+20%
|
4 420
+8%
|
4 152
-6%
|
3 400
-18%
|
|
EPS (Diluted) |
0.07
N/A
|
0.1
+43%
|
0.16
+60%
|
0.21
+31%
|
0.25
+19%
|
0.32
+28%
|
0.4
+25%
|
0.64
+60%
|
0.77
+20%
|
0.93
+21%
|
1.01
+9%
|
0.95
-6%
|
0.77
-19%
|